For Eli Lilly, total 2024 revenue was $45.04 billion, of which GLP-1 drugs generated $16.4 billion, representing 37% of total revenues
The paper describes research by design and action developed in marginal parts of the inner city of Trieste, a medium-sized Italian city facing population aging and decline, economic distress, gentrification, and rising pressure on welfare facilities
Thus, these results suggest that GLP-1RAs exhibit superior preventive effects on atherosclerotic CV events and can improve CV prognosis in T2D patients with a previous history of CV events (except ACS), and that such treatment effects could become apparent by, for example, comparing the results of CV outcomes trials with another class of incretin-based agents, namely dipeptidyl peptidase-4 (DPP-4) inhibitors [31,32,33]
Ethics declarations Conflict of interest The authors have no conflicts of interest to declare